Analysts See $-0.01 EPS for Antibe Therapeutics Inc (ATE)

November 15, 2017 - By Adrian Erickson

 Analysts See $ 0.01 EPS for Antibe Therapeutics Inc (ATE)

Analysts expect Antibe Therapeutics Inc (CVE:ATE) to report $-0.01 EPS on December, 5.They anticipate $0.00 EPS change or 0.00 % from last quarter’s $-0.01 EPS. After having $-0.02 EPS previously, Antibe Therapeutics Inc’s analysts see -50.00 % EPS growth. The stock increased 5.56% or $0.005 on November 14, reaching $0.095. About 499,000 shares traded or 97.41% up from the average. Antibe Therapeutics Inc (CVE:ATE) has 0.00% since November 15, 2016 and is . It has underperformed by 16.70% the S&P500.

Antibe Therapeutics Inc. is a commercial-stage pharmaceutical company. The company has market cap of $15.48 million. The Firm is focused on pain, inflammation and regenerative medicine. It currently has negative earnings. The Company’s divisions include Antibe Therapeutics, and Citagenix, which is a marketer and distributor of regenerative medicines serving the dental and orthopedic market places.

More notable recent Antibe Therapeutics Inc (CVE:ATE) news were published by: which released: “Antibe Therapeutics Enters into Regional Licensing Deal” on February 24, 2017, also with their article: “Antibe Therapeutics Announces Key US Distribution Partnership for Its …” published on October 26, 2017, published: “Antibe Therapeutics to Attend 2017 CPhI Worldwide Conference to Continue …” on October 20, 2017. More interesting news about Antibe Therapeutics Inc (CVE:ATE) were released by: and their article: “Antibe Therapeutics Announces Enrollment of First Subjects in Phase 2B GI …” published on September 08, 2017 as well as‘s news article titled: “Antibe Therapeutics Announces Strategic Transactions” with publication date: October 06, 2015.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.